Novo Nordisk A/S
NVO evidence brief
What we can confirm
- BioSniper Score:
- 8.2 / 10
- Market Cap:
- $168.54B
- Lead Asset:
- awiqli flextouch (Approved)
What it means
What to watch
Prepared research question
What matters most for NVO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NVO
Novo Nordisk A/S is a Danish healthcare company focused on diabetes, obesity, and specialty therapies, with its Wegovy franchise driving recent growth and a pipeline targeting multiple blockbusters by 2030.
Key risk: Semaglutide patent expiries
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$168.54B
Cash Runway
—
Lead Asset
awiqli flextouch (Approved)
Next Catalyst
Phase3_Start · Oct 26, 2026Tracking 2 pipeline candidates · 525 clinical trials · 7 catalysts · 2 FDA decisions for Novo Nordisk A/S.
Similar companies
Novo Nordisk A/S is a Danish healthcare company focused on diabetes, obesity, and specialty therapies, with its Wegovy franchise driving recent growth and a pipeline targeting multiple blockbusters by 2030.
- Adjusted sales growth of 2% at CER and adjusted operating profit growth of 2% at CER for the period ending July 2026 [sec · filed 2026-08-04].
- Wegovy pill reached more than 5 million total weekly prescriptions (TRx) since launch, with over 265,000 weekly TRx in the US as of mid-July 2026 [sec · filed 2026-08-04].
- DKK 21.7 billion invested in R&D and DKK 27.1 billion in commercial investments; DKK 41.2 billion returned to shareholders [sec · filed 2026-08-04].
- Q2 2026 included DKK 6.3 billion non-recurring, non-cash impairment charges related to intangible pipeline assets, including monlunabant (DKK 4.0 billion) [sec · filed 2026-08-04].
- Company targets five multi-blockbusters by 2030 and has set a pipeline sales target above $23 billion by 2035 [news · published 2026-09-24].
What works
- Wegovy franchise remains the market leader among branded obesity medications in the US by new patient starts [sec · filed 2026-08-04].
- Strong pipeline momentum with multiple phase 3 initiations planned for Zenagamtide (oral and subcutaneous), CagriSema, and other assets [sec · filed 2026-08-04].
- Exclusive license for a once-weekly oral GLP-1/GIP dual agonist from Hengrui Pharma adds a novel late-stage asset [news · published 2026-09-29].
- Company has raised its 2026 guidance for both adjusted sales and adjusted operating profit, reflecting confidence in growth [sec · filed 2026-08-04].
What to weigh
- Semaglutide patent expiries starting in 2037 (Liraglutide) and 2038 (Semaglutide) could pressure revenue concentration in diabetes and obesity care [news · published 2026-09-24].
- Q2 2026 included DKK 6.3 billion in non-recurring, non-cash impairment charges related to pipeline asset terminations, including monlunabant [sec · filed 2026-08-04].
- Financial guidance excludes the impact of any new significant business development transactions and assumes stable currency levels versus the Danish krone [sec · filed 2026-08-04].
- The company's long-term growth depends on pipeline execution to offset upcoming patent expiries, with some key trials (e.g., UBT251 phase 2) not expected to read out until end of 2027 [sec · filed 2026-08-04].
From the filings
Quoted directly from source documents.
Wegovy pill has achieved over 5 million total prescriptions since launch and over 265,000 weekly TRx in the US.
“ending 17 July of around 575,000-including more than 265,000 weekly TRx for Wegovy®pill, with best-in-class GLP-1 volume launch and now more than 5 million TRx since launch.”
SEC filings · August 4, 2026
Q2 2026 included DKK 6.3 billion non-recurring, non-cash impairment charges related to intangible pipeline assets.
“Excl. DKK 6.3 billion non-recurring, non-cash impairment charges in Q2 2026 related to intangible pipeline assets, including monlunabant (DKK 4.0 billion).”
SEC filings · August 4, 2026
Novo Nordisk targets five multi-blockbusters by 2030.
“Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains Traction”
News · September 21, 2026
Company entered an exclusive license for a once-weekly oral GLP-1/GIP dual agonist.
“Novo Nordisk (CPSE:NOVO B) entered an exclusive license with Hengrui Pharma for a once-weekly oral GLP-1/GIP dual agonist.”
News · September 29, 2026
Catalyst timeline
- 2026-10-26 · Phase3_Start: Zenagamtide Use for the Reduction of Risk of Major Adverse Cardiovascular Events in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity — Initiation of a phase 3 cardiovascular outcomes trial for Zenagamtide, which could expand Wegovy's label and market.
- 2027-01-07 · Phase3_Start: Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13) — Start of a phase 3 trial for subcutaneous Zenagamtide in Asian populations, supporting geographic expansion.
- 2037-01-09 · Patent_Expiry · LIRAGLUTIDE — Patent_Expiry: NDA206321 — Patent expiry for liraglutide, potentially opening the market to generics.
- 2038-10-10 · Patent_Expiry · SEMAGLUTIDE — Patent_Expiry: NDA209637 — First semaglutide patent expiry, which could impact revenue from key diabetes and obesity products.
- 2038-10-12 · Patent_Expiry · NEDOSIRAN SODIUM — Patent_Expiry: NDA215842 — Patent expiry for nedosiran sodium, a rare disease asset.
- 2039-02-01 · Patent_Expiry · SEMAGLUTIDE — Patent_Expiry: NDA213051 — Second semaglutide patent expiry, further increasing generic competition.
- 2041-02-17 · Patent_Expiry · SEMAGLUTIDE — Patent_Expiry: NDA215256 — Final semaglutide patent expiry, marking the end of exclusivity for all major semaglutide formulations.
Risks & what to watch (4)›
Key risks
- Semaglutide patent expiries — Patent expiries for semaglutide formulations begin in 2038, potentially reducing revenue concentration in diabetes and obesity care [news · published 2026-09-24].
- Pipeline asset impairments — Q2 2026 included DKK 6.3 billion non-cash impairment charges from terminated pipeline assets, including monlunabant [sec · filed 2026-08-04].
- Currency and guidance assumptions — Financial guidance assumes stable currency levels versus the Danish krone and excludes new business development transactions [sec · filed 2026-08-04].
- Pipeline execution dependency — Long-term growth relies on pipeline success to offset patent expiries; some key trials read out as late as end of 2027 [sec · filed 2026-08-04].
What to watch
- Phase 3 initiation of Zenagamtide for cardiovascular outcomes in people with obesity (expected Q4 2026) [sec · filed 2026-08-04].
- US regulatory decision for CagriSema in obesity (expected Q4 2026) [sec · filed 2026-08-04].
- Phase 2 readout for Triple (amylin analog) in obesity (expected Q1 2027) [sec · filed 2026-08-04].
- Phase 2 readout for UBT251 in type 2 diabetes (expected end of 2027) [sec · filed 2026-08-04].
Sources: News · SEC filings · Generated October 12, 2026 · How we verify sources →
Run Novo Nordisk A/S through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Novo Nordisk A/S facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
2 candidates
7 upcoming, next in ~12d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 0.4%
- Days to cover
- 0.8
- Shares short
- 13,996,269
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NVO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Novo Nordisk A/S?
Novo Nordisk A/S is a Danish healthcare company focused on diabetes, obesity, and specialty therapies, with its Wegovy franchise driving recent growth and a pipeline targeting multiple blockbusters by 2030.
What is Novo Nordisk A/S's lead drug candidate?
Novo Nordisk A/S's most advanced tracked candidate is awiqli flextouch (Approved).
What is Novo Nordisk A/S's next catalyst?
Novo Nordisk A/S's next tracked catalyst is a Phase3_Start event — "Phase3_Start: Zenagamtide Use for the Reduction of Risk of Major Adverse Cardiovascular Events in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity" — expected October 26, 2026.
Who is the CEO of Novo Nordisk A/S?
Mr. Maziar Mike Doustdar B.A. is the chief executive officer of Novo Nordisk A/S (NVO).
Where is Novo Nordisk A/S headquartered?
Novo Nordisk A/S (NVO) is headquartered in Bagsvaerd, Denmark.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.